Patents by Inventor Lisa Mcqueen

Lisa Mcqueen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL PHARMACEUTICAL FORMULATION
    Publication number: 20220362253
    Abstract: Disclosed are novel pharmaceutical formulations comprising (E)-1-(4-(5-Carbamoyl-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-7-(3-morpholinopropoxy)-1H-benzo[d]imidazol-1-yl)but-2-en-1-yl)-2-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-7-methoxy-1H-benzo[d]imidazole-5-carboxamide, processes for preparing the same, and methods of using the same.
    Type: Application
    Filed: December 4, 2019
    Publication date: November 17, 2022
    Inventors: Lisa McQUEEN, Anand Babu DHANIKULA
  • Inhibiting the transient receptor potential A1 ion channel
    Patent number: 10428072
    Abstract: The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: October 1, 2019
    Assignee: Eli Lilly and Company
    Inventors: Blaise S. Lippa, Xinyuan Wu, Qingyi Li, Iwona Wrona, Andrew J. Jackson, Bertrand L. Chenard, Christopher M. Liu, Guohua Liang, Matthew F. Baevsky, Richard A. Earl, Lisa Mcqueen, Jared Smit, Brett A. Cowans
  • INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL
    Publication number: 20180230149
    Abstract: The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
    Type: Application
    Filed: March 29, 2018
    Publication date: August 16, 2018
    Inventors: Blaise S. Lippa, Xinyuan Wu, Qingyi Li, Iwona Wrona, Andrew J. Jackson, Bertrand L. Chenard, Christopher M. Liu, Guohua Liang, Matthew F. Baevsky, Richard A. Earl, Lisa Mcqueen, Jared Smit, Brett A. Cowans
  • INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL
    Publication number: 20170050966
    Abstract: The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
    Type: Application
    Filed: April 23, 2015
    Publication date: February 23, 2017
    Inventors: Blaise S. Lippa, Xinyuan Wu, Qingyi Li, Iwona Wrona, Andrew J. Jackson, Bertrand L. Chenard, Christopher Matthew Liu, Guohua Liang, Matthew F. Baevsky, Richard Alan Earl, Lisa Mcqueen, Jared Smit, Brett A. Cowans